NCT02537366

Dexmedetomidine for Non-invasive Ventilation After Chest Trauma

Dexmedetomidine for Non-invasive Ventilation After Chest Trauma (VENDETTA)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University Hospital, Grenoble · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Crossover randomized controlled double blinded trial : * The primary endpoint is the duration of Non Invasive Ventilation (NIV) session (minutes) with dexmedetomidine (DEX) or placebo. * Secondary endpoints will be the sedation level as assessed by the Richmond Agitation Sedation Scale (RASS), the number of interventions to allow the completion of NIV session, the pain intensity level as assessed by visual analogue scale, the morphine and ketamine consumption during NIV sessions, the comparison of blood gas measurements before and after NIV sessions, the reproducibility of NIV cycles. The side effects of DEX will be notified.

Conditions

• Thoracic Injuries

Interventions

Type	Name	Description
DRUG	Dexmedetomidine
DRUG	Placebo

Timeline

• Start date: 2015-09-01
• Primary completion: 2017-02-01
• Completion: 2017-02-01
• First posted: 2015-09-01
• Last updated: 2017-03-09

Locations

1 site across 1 country: France